VERSANT VENTURE MANAGEMENT LLC
Q3 2025 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001560009
· CRD 161130
· Exempt reporting adviser
$212.5M Reported Value Total
VERSANT VENTURE MANAGEMENT, LLC reports under management (AUM).
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Exempt Reporting Adviser
WWW.VERSANTVENTURES.COM
Source: Form ADV filed 2026-03-30
Reported value
$212.5M
Quarter over quarter
+35.6%
Holdings
9
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Max Eisenberg
Chief Operating Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2025 13F record
Q3 2025 13F filing summary
| Period of report | September 30, 2025 |
|---|---|
| Filed | November 10, 2025 |
| Form | 13F-HR |
| Reported value | $212.5M |
| Positions | 9 |
| Change in reported value | +158.7% |
| New positions | 1 |
| Exited positions | 0 |
| Position turnover | 11.1% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
8 | $109.1M |
|
Q2 2026 13F
Filed Aug 12, 2026
|
8 | $162.6M |
|
Q1 2026 13F
Filed May 5, 2026
|
8 | $141.4M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
7 | $151.1M |
|
Q3 2025 13F
Filed Nov 10, 2025
|
9 | $212.5M |
|
Q2 2025 13F
Filed Aug 11, 2025
|
8 | $82.1M |
|
Q1 2025 13F
Filed May 7, 2025
|
7 | $60.2M |
|
Q4 2024 13F
Filed Feb 12, 2025
|
7 | $86.7M |
|
Q3 2024 13F
Filed Nov 8, 2024
|
6 | $63.6M |
|
Q2 2024 13F
Filed Aug 7, 2024
|
8 | $77.3M |
|
Q1 2024 13F
Filed May 3, 2024
|
7 | $103.1M |
|
Q4 2023 13F
Filed Feb 8, 2024
|
7 | $388.8M |
|
Q3 2023 13F
Filed Nov 3, 2023
|
8 | $188.1M |
|
Q2 2023 13F
Filed Aug 9, 2023
|
8 | $84.3M |
|
Q1 2023 13F
Filed May 11, 2023
|
7 | $48.0M |
|
Q4 2022 13F
Filed Feb 9, 2023
|
7 | $48.3M |
|
Q3 2022 13F
Filed Nov 10, 2022
|
8 | $58.7M |
|
Q2 2022 13F
Filed Aug 11, 2022
|
8 | $65.2M |
|
Q1 2022 13F
Filed May 10, 2022
|
10 | $100.2M |
|
Q4 2021 13F
Filed Feb 11, 2022
|
10 | $187.0M |
28 earlier quarters on file — choose one from the quarter menu above.
Top 9 holdings · Q3 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | LENZ Lenz Therapeutics, Inc. | $123.8M | 58.25% |
| 2 | GLUE Monte Rosa Therapeutics, Inc. | $41.9M | 19.72% |
| 3 | JBIO Jade Biosciences, Inc. | $13.2M | 6.2% |
| 4 | CRSP CRISPR Therapeutics AG | $9.6M | 4.54% |
| 5 | SKYE Skye Bioscience, Inc. | $7.9M | 3.71% |
| 6 | CTNM Contineum Therapeutics, Inc. | $6.4M | 3.0% |
| 7 | RPTX Repare Therapeutics, Inc. | $4.7M | 2.19% |
| 8 | TPST Tempest Therapeutics, Inc. | $2.8M | 1.31% |
| 9 | ADVM Adverum Biotechnologies, Inc. | $2.3M | 1.08% |
Values as reported on the Q3 2025 Form 13F. Every position is in the holdings table below.